Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.54 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | BLM | P54132 | 1/20 | 0.54 |
| ▸ | APAF1 | O14727 | 1/20 | 0.47 |
| ▸ | CASP6 | P55212 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 6/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.42 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27620150 | 0.82 | CYP3A4 (0.40) | ALDH1A1CYP3A4PMP22LMNAMAPT | |
| SCHEMBL8359284 | 0.76 | PDE1A (0.39) | ALDH1A1CYP3A4PMP22LMNAMAPT | |
| SCHEMBL2948723 | 0.76 | GAA (0.53) | ALDH1A1TSHRKDM4EMEN1KMT2A | |
| SCHEMBL7367989 | 0.75 | ALDH1A1 (0.46) | ALDH1A1CYP3A4PMP22LMNAMAPT | |
| SCHEMBL1892896 | 0.75 | APAF1 (0.39) | ALDH1A1CYP3A4PMP22LMNAMAPT | |
| Paraxanthine SCHEMBL13384565 | 0.73 | CYP3A4 (0.81) | ALDH1A1CYP3A4PMP22LMNAMAPT | |
| SCHEMBL7270657 | 0.72 | KDM4E (0.41) | ALDH1A1CYP3A4PMP22LMNAMAPT | |
| SCHEMBL10432471 | 0.72 | HSD17B10 (0.49) | ALDH1A1LMNAMAPK1KDM4EMEN1 | |
| SCHEMBL10998 | 0.72 | GDA (0.53) | ALDH1A1CYP3A4PMP22LMNAMAPT | |
| SCHEMBL4560085 | 0.72 | GDA (0.53) | ALDH1A1CYP3A4PMP22LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050148067-A1 | Materials and methods for binding nucleic acids to surfaces | LYLES MARK B (US) | 2005-07-07 | — | — | US | claimed |
| US-6855817-B2 | Materials and methods for binding nucleic acids to surfaces | LYLES MARK B (US) | 2005-02-15 | — | — | US | claimed |
| US-20040013609-A1 | For identification of substances for treatment or prevention of insufficient longitudinal growth of eye(hypermetropia) or excessive longitudinal growth of eye(myopia); involves measurement of effect on retinal pigment epithelium | TRIER KLAUS (DK) | 2004-01-22 | — | — | US | claimed |
| EP-1305328-A2 | MATERIALS AND METHODS FOR BINDING NUCLEIC ACIDS TO SURFACES | Lyles, Mark B. (US) | 2003-05-02 | — | — | EP | claimed |
| US-20020103350-A1 | Materials and methods for binding nucleic acids to surfaces | LYLES MARK B (US) | 2002-08-01 | — | — | US | claimed |
| WO-2002008237-A2 | MATERIALS AND METHODS FOR BINDING NUCLEIC ACIDS TO SURFACES | LYLES MARK B (US) | 2002-01-31 | — | — | WO | claimed |
| WO-1998030900-A2 | SCREENING METHOD FOR COMPOUNDS ACTIVE IN TREATING MYOPIA AND HYPERMETROPIA | KLAUS TRIER APS (DK) | 1998-07-16 | — | — | WO | claimed |
| US-20250386846-A1 | Food Compositions Including Aragonite | NANT HOLDINGS IP LLC (US) | 2025-12-25 | — | — | US | disclosed |
| US-12419336-B2 | Beverage compositions including calcium supplied from aragonite and methods of making the same | NANT HOLDINGS IP, LLC (US) | 2025-09-23 | — | — | US | disclosed |
| WO-2025133718-A1 | AN EFFICIENT PROCESS FOR THE SYNTHESIS OF PARAXANTHINE | FERTIS INDIA PVT. LTD. (IN) | 2025-06-26 | — | — | WO | disclosed |
| US-20250194654-A1 | Beverage Compositions Including Calcium Supplied From Aragonite And Methods Of Making The Same | NANT HOLDINGS IP, LLC | 2025-06-19 | — | — | US | disclosed |
| US-12310392-B2 | Beverage compositions including calcium supplied from aragonite and methods of making the same | NANT HOLDINGS IP, LLC (US) | 2025-05-27 | — | — | US | disclosed |
| US-20240381918-A1 | Beverage Compositions Including Calcium Supplied From Aragonite And Methods Of Making The Same | NANT HOLDINGS IP, LLC | 2024-11-21 | — | — | US | disclosed |
| EP-1196050-A1 | COMPOSITIONS, KITS, AND METHODS FOR PROVIDING AND MAINTAINING ENERGY AND MENTAL ALERTNESS | THE PROCTER & GAMBLE COMPANY (US) | 2002-04-17 | — | — | EP | disclosed |
| WO-2002026055-A2 | BEVERAGE COMPOSITIONS COMPRISING ARABINOGALACTAN AND DEFINED VITAMINS | THE PROCTER & GAMBLE COMPANY (US) | 2002-04-04 | — | — | WO | disclosed |
| WO-2002026053-A2 | BEVERAGE COMPOSITIONS COMPRISING ARABINOGALACTAN AND MINERAL SUPPLEMENT | THE PROCTER & GAMBLE COMPANY (US) | 2002-04-04 | — | — | WO | disclosed |
| WO-2002008237-A2 | MATERIALS AND METHODS FOR BINDING NUCLEIC ACIDS TO SURFACES | LYLES MARK B (US) | 2002-01-31 | — | — | WO | disclosed |
| WO-2001093847-A2 | COMPOSITIONS, KITS, AND METHODS FOR PROMOTING DEFINED HEALTH BENEFITS | THE PROCTER & GAMBLE COMPANY (US) | 2001-12-13 | — | — | WO | disclosed |
| WO-2001005253-A1 | COMPOSITIONS, KITS, AND METHODS FOR PROVIDING AND MAINTAINING ENERGY AND MENTAL ALERTNESS | THE PROCTER & GAMBLE COMPANY (US) | 2001-01-25 | — | — | WO | disclosed |
| WO-1998030900-A2 | SCREENING METHOD FOR COMPOUNDS ACTIVE IN TREATING MYOPIA AND HYPERMETROPIA | KLAUS TRIER APS (DK) | 1998-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040013609-A1 | For identification of substances for treatment or prevention of insufficient longitudinal growth of eye(hypermetropia) or excessive longitudinal growth of eye(myopia); involves measurement of effect on retinal pigment epithelium | RYR1, ATP2A2, ATP2A1 | ALDH1A1 1550/4885CYP3A4 4148/4885PMP22 1018/4885 |
| US-20250386846-A1 | Food Compositions Including Aragonite | PLCG2, PLCG1, PLCB3 | ALDH1A1 4338/4885CYP3A4 4435/4885PMP22 3777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.